Immix Biopharma (NASDAQ:IMMX) Earns Outperform Rating from Analysts at Mizuho

Mizuho started coverage on shares of Immix Biopharma (NASDAQ:IMMX) in a research note issued to investors on Monday, MarketBeat reports. The brokerage issued an outperform rating and a $14.00 target price on the stock.

IMMX has been the topic of a number of other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Immix Biopharma in a report on Thursday, January 22nd. Wall Street Zen upgraded Immix Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, January 31st. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $11.00.

Immix Biopharma Price Performance

Immix Biopharma stock opened at $6.84 on Monday. Immix Biopharma has a 12-month low of $1.34 and a 12-month high of $7.73. The stock has a market capitalization of $362.25 million, a PE ratio of -8.88 and a beta of 0.31. The firm has a 50 day simple moving average of $5.65 and a 200-day simple moving average of $3.81.

Institutional Trading of Immix Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of IMMX. Velan Capital Investment Management LP purchased a new position in Immix Biopharma in the second quarter valued at about $52,000. Vanguard Group Inc. lifted its holdings in shares of Immix Biopharma by 4.5% during the 3rd quarter. Vanguard Group Inc. now owns 730,162 shares of the company’s stock valued at $1,526,000 after buying an additional 31,625 shares during the last quarter. Tocqueville Asset Management L.P. grew its stake in shares of Immix Biopharma by 37.4% in the 3rd quarter. Tocqueville Asset Management L.P. now owns 40,250 shares of the company’s stock valued at $84,000 after buying an additional 10,950 shares in the last quarter. Imprint Wealth LLC bought a new stake in shares of Immix Biopharma in the 3rd quarter valued at approximately $141,000. Finally, Citadel Advisors LLC acquired a new position in Immix Biopharma in the third quarter worth approximately $188,000. 11.26% of the stock is currently owned by hedge funds and other institutional investors.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.